MICROPORT NEURO (02172): NuWismen Zhiji Liquid Embolic Agent Enters NMPA Innovation Green Channel

MICROPORT NEURO (02172) announced that the NuWismen Zhiji Liquid Embolic Agent developed by the Group has passed the NMPA Innovative Medical Device Special Review application and entered the special review procedure (green channel). This selection marks the Group's 8th product included in the NMPA Innovative Medical Device Special Review, completing the product portfolio for the cerebrovascular malformation treatment segment and further enhancing the coverage capability of the Group's full-scenario interventional solutions for cerebrovascular diseases. Cerebrovascular malformations include common lesions such as brain arteriovenous malformations (bAVM) and dural arteriovenous fistulas (dAVF). For complex lesions that are deeply located, involve eloquent areas, or are complicated by aneurysms or high-flow fistulas, interventional embolization is the preferred clinical choice and an important means of combination therapy. The Group is committed to the development and promotion of innovative solutions. It currently has 29 neurointerventional products, covering major diseases such as aneurysms, stenosis, and thrombectomy. Eight of the Group's products have been included in the NMPA Innovative Medical Device green channel. The other seven are the Tubridge Flow-Diverter Stent, the Bridge Vertebral Artery Rapamycin-Targeted Eluting Stent, the Tigertriever Intracranial Thrombectomy Stent, the Rebridge Intracranial Artery Stent, the StraitPass Disposable Hematoma Aspiration Device, the NuFairy Absorbable Coil, and the Artemis Dream Self-Expanding Intracranial Rapamycin-Eluting Stent System, among which three have already been launched and promoted.